Philogen S.p.A. (BIT:PHIL)
Italy · Delayed Price · Currency is EUR | Market Cap | 910.36M -2.7% |
| Revenue (ttm) | 315.27M +272.4% |
| Net Income | 224.98M +390.0% |
| EPS | n/a |
| Shares Out | 40.28M |
| PE Ratio | 4.05 |
| Forward PE | n/a |
| Dividend | 0.70 (3.10%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | 25,031 |
| Open | 22.40 |
| Previous Close | 22.20 |
| Day's Range | 22.10 - 22.85 |
| 52-Week Range | 19.56 - 26.00 |
| Beta | -0.02 |
| Analysts | Buy |
| Price Target | 27.67 (+22.43%) |
| Earnings Date | Sep 23, 2026 |
About Philogen
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment... [Read more]
Financial Performance
In 2025, Philogen's revenue was 319.73 million, an increase of 313.81% compared to the previous year's 77.26 million. Earnings were 229.68 million, an increase of 407.10%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PHIL stock is "Buy." The 12-month stock price target is €27.67, which is an increase of 22.43% from the latest price.
News
Philogen Earnings Call Transcript: Q2 2026
Clinical pipeline advanced with pivotal data for lead oncology assets, strong cash reserves over €300 million, and multiple registration trials progressing toward completion by 2028–2029. Regulatory alignment achieved for most programs, with milestone-based revenues expected.
Philogen Earnings release: Q2 2026
Philogen released its Q2 2026 earnings on September 25, 2026, summarizing the period's financial results.
Philogen Quarterly report: Q2 2026
Philogen has published its Q2 2026 quarterly earnings report on September 25, 2026.
Philogen Earnings release: Q1 2026
Philogen released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Philogen Earnings Call Transcript: H2 2025
Reported EUR 230 million net profit and EUR 380 million cash for 2025, with a EUR 0.70 dividend per share. Advanced key oncology programs, including Nidlegy and Fibromun, and secured major licensing deals. Regulatory submissions and pivotal trials are on track.
Philogen Annual report: H2 2025
Philogen has published its H2 2025 annual report on March 30, 2026.
Philogen Earnings release: H2 2025
Philogen released its H2 2025 earnings on March 30, 2026, summarizing the period's financial results.
Philogen Earnings release: Q3 2025
Philogen released its Q3 2025 earnings on November 11, 2025, summarizing the period's financial results.
Philogen Earnings Call Transcript: H1 2025
A transformative licensing deal with Racebio has significantly strengthened liquidity, enabling expanded investment in late-stage clinical programs and infrastructure. Key trials in oncology and dermatology are progressing, with major data readouts and regulatory milestones expected in 2025–2026.
Philogen Quarterly report: H1 2025
Philogen has published its H1 2025 quarterly earnings report on September 26, 2025.
Philogen Earnings release: H1 2025
Philogen released its H1 2025 earnings on September 26, 2025, summarizing the period's financial results.